At discharge, 75.9% patients with MINOCA were treated with a single antiplatelet drug (aspirin or P2Y12 inhibitor) and only 42.1% with dual antiplatelet therapy (DAPT), compared with 94.6% and 81.8% ob-CAD patients. This evidence concerns the gene P2RY12 and coronary artery disorder.